Loading…

An NMR Protocol for In Vitro Paclitaxel Release from an Albumin-Bound Nanoparticle Formulation

The paclitaxel protein-bound particles for injectable suspension (marketed under the brand name Abraxane®) contains nanosized complexes of paclitaxel and albumin. The molecular interaction between paclitaxel and albumin within the higher-order nanostructure is analytically challenging to assess, as...

Full description

Saved in:
Bibliographic Details
Published in:AAPS PharmSciTech 2020-05, Vol.21 (5), p.136-136, Article 136
Main Authors: Suh, Min Sung, Patil, Sharadrao M., Kozak, Darby, Pang, Eric, Choi, Stephanie, Jiang, Xiaohui, Rodriguez, Jason D., Keire, David A., Chen, Kang
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c347t-e43950bca439c2aac743814aa6204a169bf8638512a72e9416a6837a3838b9713
cites cdi_FETCH-LOGICAL-c347t-e43950bca439c2aac743814aa6204a169bf8638512a72e9416a6837a3838b9713
container_end_page 136
container_issue 5
container_start_page 136
container_title AAPS PharmSciTech
container_volume 21
creator Suh, Min Sung
Patil, Sharadrao M.
Kozak, Darby
Pang, Eric
Choi, Stephanie
Jiang, Xiaohui
Rodriguez, Jason D.
Keire, David A.
Chen, Kang
description The paclitaxel protein-bound particles for injectable suspension (marketed under the brand name Abraxane®) contains nanosized complexes of paclitaxel and albumin. The molecular interaction between paclitaxel and albumin within the higher-order nanostructure is analytically challenging to assess, as is any correlation of differences to differences in therapeutic effect. However, because the higher-order nanostructures may affect the paclitaxel release, a suitable in vitro assay to detect potential differences in paclitaxel release between comparator lots and products is desirable. Herein, solution NMR spectroscopy with a T 2 -filtering technique was developed to detect paclitaxel signal while suppressing albumin signals to follow the released paclitaxel in the NMR tube upon dilution. The non-invasive nature of NMR allows for precise measurement of a full range of dilution-induced drug release percentage from 14 to 92% without any sample extraction. The critical concentration of the drug product (DP) at 50% of release was 0.63 ± 0.04 mg/mL in PBS buffer. In addition, 2D diffusion ordered NMR spectroscopy (DOSY) results revealed that the released paclitaxel experiencing slightly slowed diffusion rates than free paclitaxel, which was attributed to paclitaxel in equilibrium with albumin-bound states. Collectively, the dilution-based NMR method offered an analytical approach to investigate physicochemical attributes of complex injectable products with minimal needed sample preparation and perturbation to nanoparticle formulation.
doi_str_mv 10.1208/s12249-020-01669-1
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2404373461</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2404373461</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-e43950bca439c2aac743814aa6204a169bf8638512a72e9416a6837a3838b9713</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlb_gAfJ0ctqvrq7OdZitVBrKerRMJtmZUs2qcku6L93a6t48jQD87wvzIPQOSVXlJH8OlLGhEwIIwmhaSoTeoD6dMhJIiVnh3_2HjqJcU0I41TyY9TjTFDZpfvodeTw_GGJF8E3XnuLSx_w1OGXqgkeL0DbqoEPY_HSWAPR4DL4GoPDI1u0deWSG9-6FZ6D8xsITaWtwRMf6tZCU3l3io5KsNGc7ecAPU9un8b3yezxbjoezRLNRdYkRnA5JIWGbmoGoDPBcyoAUkYE0FQWZZ7yfEgZZMxIQVNIc54Bz3leyIzyAbrc9W6Cf29NbFRdRW2sBWd8GxUTRPCMi3SLsh2qg48xmFJtQlVD-FSUqK1XtfOqOq_q26vahi72_W1Rm9Vv5EdkB_AdELuTezNBrX0bXPfzf7Vf_uGBew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2404373461</pqid></control><display><type>article</type><title>An NMR Protocol for In Vitro Paclitaxel Release from an Albumin-Bound Nanoparticle Formulation</title><source>Springer Nature</source><creator>Suh, Min Sung ; Patil, Sharadrao M. ; Kozak, Darby ; Pang, Eric ; Choi, Stephanie ; Jiang, Xiaohui ; Rodriguez, Jason D. ; Keire, David A. ; Chen, Kang</creator><creatorcontrib>Suh, Min Sung ; Patil, Sharadrao M. ; Kozak, Darby ; Pang, Eric ; Choi, Stephanie ; Jiang, Xiaohui ; Rodriguez, Jason D. ; Keire, David A. ; Chen, Kang</creatorcontrib><description>The paclitaxel protein-bound particles for injectable suspension (marketed under the brand name Abraxane®) contains nanosized complexes of paclitaxel and albumin. The molecular interaction between paclitaxel and albumin within the higher-order nanostructure is analytically challenging to assess, as is any correlation of differences to differences in therapeutic effect. However, because the higher-order nanostructures may affect the paclitaxel release, a suitable in vitro assay to detect potential differences in paclitaxel release between comparator lots and products is desirable. Herein, solution NMR spectroscopy with a T 2 -filtering technique was developed to detect paclitaxel signal while suppressing albumin signals to follow the released paclitaxel in the NMR tube upon dilution. The non-invasive nature of NMR allows for precise measurement of a full range of dilution-induced drug release percentage from 14 to 92% without any sample extraction. The critical concentration of the drug product (DP) at 50% of release was 0.63 ± 0.04 mg/mL in PBS buffer. In addition, 2D diffusion ordered NMR spectroscopy (DOSY) results revealed that the released paclitaxel experiencing slightly slowed diffusion rates than free paclitaxel, which was attributed to paclitaxel in equilibrium with albumin-bound states. Collectively, the dilution-based NMR method offered an analytical approach to investigate physicochemical attributes of complex injectable products with minimal needed sample preparation and perturbation to nanoparticle formulation.</description><identifier>ISSN: 1530-9932</identifier><identifier>EISSN: 1530-9932</identifier><identifier>DOI: 10.1208/s12249-020-01669-1</identifier><identifier>PMID: 32419122</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Pharmacology/Toxicology ; Pharmacy ; Research Article</subject><ispartof>AAPS PharmSciTech, 2020-05, Vol.21 (5), p.136-136, Article 136</ispartof><rights>American Association of Pharmaceutical Scientists 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-e43950bca439c2aac743814aa6204a169bf8638512a72e9416a6837a3838b9713</citedby><cites>FETCH-LOGICAL-c347t-e43950bca439c2aac743814aa6204a169bf8638512a72e9416a6837a3838b9713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32419122$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suh, Min Sung</creatorcontrib><creatorcontrib>Patil, Sharadrao M.</creatorcontrib><creatorcontrib>Kozak, Darby</creatorcontrib><creatorcontrib>Pang, Eric</creatorcontrib><creatorcontrib>Choi, Stephanie</creatorcontrib><creatorcontrib>Jiang, Xiaohui</creatorcontrib><creatorcontrib>Rodriguez, Jason D.</creatorcontrib><creatorcontrib>Keire, David A.</creatorcontrib><creatorcontrib>Chen, Kang</creatorcontrib><title>An NMR Protocol for In Vitro Paclitaxel Release from an Albumin-Bound Nanoparticle Formulation</title><title>AAPS PharmSciTech</title><addtitle>AAPS PharmSciTech</addtitle><addtitle>AAPS PharmSciTech</addtitle><description>The paclitaxel protein-bound particles for injectable suspension (marketed under the brand name Abraxane®) contains nanosized complexes of paclitaxel and albumin. The molecular interaction between paclitaxel and albumin within the higher-order nanostructure is analytically challenging to assess, as is any correlation of differences to differences in therapeutic effect. However, because the higher-order nanostructures may affect the paclitaxel release, a suitable in vitro assay to detect potential differences in paclitaxel release between comparator lots and products is desirable. Herein, solution NMR spectroscopy with a T 2 -filtering technique was developed to detect paclitaxel signal while suppressing albumin signals to follow the released paclitaxel in the NMR tube upon dilution. The non-invasive nature of NMR allows for precise measurement of a full range of dilution-induced drug release percentage from 14 to 92% without any sample extraction. The critical concentration of the drug product (DP) at 50% of release was 0.63 ± 0.04 mg/mL in PBS buffer. In addition, 2D diffusion ordered NMR spectroscopy (DOSY) results revealed that the released paclitaxel experiencing slightly slowed diffusion rates than free paclitaxel, which was attributed to paclitaxel in equilibrium with albumin-bound states. Collectively, the dilution-based NMR method offered an analytical approach to investigate physicochemical attributes of complex injectable products with minimal needed sample preparation and perturbation to nanoparticle formulation.</description><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Research Article</subject><issn>1530-9932</issn><issn>1530-9932</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMotlb_gAfJ0ctqvrq7OdZitVBrKerRMJtmZUs2qcku6L93a6t48jQD87wvzIPQOSVXlJH8OlLGhEwIIwmhaSoTeoD6dMhJIiVnh3_2HjqJcU0I41TyY9TjTFDZpfvodeTw_GGJF8E3XnuLSx_w1OGXqgkeL0DbqoEPY_HSWAPR4DL4GoPDI1u0deWSG9-6FZ6D8xsITaWtwRMf6tZCU3l3io5KsNGc7ecAPU9un8b3yezxbjoezRLNRdYkRnA5JIWGbmoGoDPBcyoAUkYE0FQWZZ7yfEgZZMxIQVNIc54Bz3leyIzyAbrc9W6Cf29NbFRdRW2sBWd8GxUTRPCMi3SLsh2qg48xmFJtQlVD-FSUqK1XtfOqOq_q26vahi72_W1Rm9Vv5EdkB_AdELuTezNBrX0bXPfzf7Vf_uGBew</recordid><startdate>20200517</startdate><enddate>20200517</enddate><creator>Suh, Min Sung</creator><creator>Patil, Sharadrao M.</creator><creator>Kozak, Darby</creator><creator>Pang, Eric</creator><creator>Choi, Stephanie</creator><creator>Jiang, Xiaohui</creator><creator>Rodriguez, Jason D.</creator><creator>Keire, David A.</creator><creator>Chen, Kang</creator><general>Springer International Publishing</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200517</creationdate><title>An NMR Protocol for In Vitro Paclitaxel Release from an Albumin-Bound Nanoparticle Formulation</title><author>Suh, Min Sung ; Patil, Sharadrao M. ; Kozak, Darby ; Pang, Eric ; Choi, Stephanie ; Jiang, Xiaohui ; Rodriguez, Jason D. ; Keire, David A. ; Chen, Kang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-e43950bca439c2aac743814aa6204a169bf8638512a72e9416a6837a3838b9713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Research Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suh, Min Sung</creatorcontrib><creatorcontrib>Patil, Sharadrao M.</creatorcontrib><creatorcontrib>Kozak, Darby</creatorcontrib><creatorcontrib>Pang, Eric</creatorcontrib><creatorcontrib>Choi, Stephanie</creatorcontrib><creatorcontrib>Jiang, Xiaohui</creatorcontrib><creatorcontrib>Rodriguez, Jason D.</creatorcontrib><creatorcontrib>Keire, David A.</creatorcontrib><creatorcontrib>Chen, Kang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>AAPS PharmSciTech</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suh, Min Sung</au><au>Patil, Sharadrao M.</au><au>Kozak, Darby</au><au>Pang, Eric</au><au>Choi, Stephanie</au><au>Jiang, Xiaohui</au><au>Rodriguez, Jason D.</au><au>Keire, David A.</au><au>Chen, Kang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An NMR Protocol for In Vitro Paclitaxel Release from an Albumin-Bound Nanoparticle Formulation</atitle><jtitle>AAPS PharmSciTech</jtitle><stitle>AAPS PharmSciTech</stitle><addtitle>AAPS PharmSciTech</addtitle><date>2020-05-17</date><risdate>2020</risdate><volume>21</volume><issue>5</issue><spage>136</spage><epage>136</epage><pages>136-136</pages><artnum>136</artnum><issn>1530-9932</issn><eissn>1530-9932</eissn><abstract>The paclitaxel protein-bound particles for injectable suspension (marketed under the brand name Abraxane®) contains nanosized complexes of paclitaxel and albumin. The molecular interaction between paclitaxel and albumin within the higher-order nanostructure is analytically challenging to assess, as is any correlation of differences to differences in therapeutic effect. However, because the higher-order nanostructures may affect the paclitaxel release, a suitable in vitro assay to detect potential differences in paclitaxel release between comparator lots and products is desirable. Herein, solution NMR spectroscopy with a T 2 -filtering technique was developed to detect paclitaxel signal while suppressing albumin signals to follow the released paclitaxel in the NMR tube upon dilution. The non-invasive nature of NMR allows for precise measurement of a full range of dilution-induced drug release percentage from 14 to 92% without any sample extraction. The critical concentration of the drug product (DP) at 50% of release was 0.63 ± 0.04 mg/mL in PBS buffer. In addition, 2D diffusion ordered NMR spectroscopy (DOSY) results revealed that the released paclitaxel experiencing slightly slowed diffusion rates than free paclitaxel, which was attributed to paclitaxel in equilibrium with albumin-bound states. Collectively, the dilution-based NMR method offered an analytical approach to investigate physicochemical attributes of complex injectable products with minimal needed sample preparation and perturbation to nanoparticle formulation.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32419122</pmid><doi>10.1208/s12249-020-01669-1</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1530-9932
ispartof AAPS PharmSciTech, 2020-05, Vol.21 (5), p.136-136, Article 136
issn 1530-9932
1530-9932
language eng
recordid cdi_proquest_miscellaneous_2404373461
source Springer Nature
subjects Biochemistry
Biomedical and Life Sciences
Biomedicine
Biotechnology
Pharmacology/Toxicology
Pharmacy
Research Article
title An NMR Protocol for In Vitro Paclitaxel Release from an Albumin-Bound Nanoparticle Formulation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A37%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20NMR%20Protocol%20for%20In%20Vitro%20Paclitaxel%20Release%20from%20an%20Albumin-Bound%20Nanoparticle%20Formulation&rft.jtitle=AAPS%20PharmSciTech&rft.au=Suh,%20Min%20Sung&rft.date=2020-05-17&rft.volume=21&rft.issue=5&rft.spage=136&rft.epage=136&rft.pages=136-136&rft.artnum=136&rft.issn=1530-9932&rft.eissn=1530-9932&rft_id=info:doi/10.1208/s12249-020-01669-1&rft_dat=%3Cproquest_cross%3E2404373461%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c347t-e43950bca439c2aac743814aa6204a169bf8638512a72e9416a6837a3838b9713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2404373461&rft_id=info:pmid/32419122&rfr_iscdi=true